Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1994 7
1995 4
1996 2
1998 1
2001 1
2003 1
2005 1
2008 2
2011 1
2012 1
2013 1
2014 1
2015 2
2016 5
2017 1
2018 1
2019 5
2020 3
2021 4
2022 5
2023 2
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

53 results

Results by year

Filters applied: . Clear all
Page 1
Homologous and Heterologous Covid-19 Booster Vaccinations.
Atmar RL, Lyke KE, Deming ME, Jackson LA, Branche AR, El Sahly HM, Rostad CA, Martin JM, Johnston C, Rupp RE, Mulligan MJ, Brady RC, Frenck RW Jr, Bäcker M, Kottkamp AC, Babu TM, Rajakumar K, Edupuganti S, Dobrzynski D, Coler RN, Posavad CM, Archer JI, Crandon S, Nayak SU, Szydlo D, Zemanek JA, Dominguez Islas CP, Brown ER, Suthar MS, McElrath MJ, McDermott AB, O'Connell SE, Montefiori DC, Eaton A, Neuzil KM, Stephens DS, Roberts PC, Beigel JH; DMID 21-0012 Study Group. Atmar RL, et al. Among authors: rupp re. N Engl J Med. 2022 Mar 17;386(11):1046-1057. doi: 10.1056/NEJMoa2116414. Epub 2022 Jan 26. N Engl J Med. 2022. PMID: 35081293 Free PMC article. Clinical Trial.
Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant.
Lyke KE, Atmar RL, Islas CD, Posavad CM, Szydlo D, Paul Chourdhury R, Deming ME, Eaton A, Jackson LA, Branche AR, El Sahly HM, Rostad CA, Martin JM, Johnston C, Rupp RE, Mulligan MJ, Brady RC, Frenck RW Jr, Bäcker M, Kottkamp AC, Babu TM, Rajakumar K, Edupuganti S, Dobrzynski D, Coler RN, Archer JI, Crandon S, Zemanek JA, Brown ER, Neuzil KM, Stephens DS, Post DJ, Nayak SU, Suthar MS, Roberts PC, Beigel JH, Montefiori DC; DMID 21-0012 Study Group. Lyke KE, et al. Among authors: rupp re. Cell Rep Med. 2022 Jul 19;3(7):100679. doi: 10.1016/j.xcrm.2022.100679. Epub 2022 Jun 20. Cell Rep Med. 2022. PMID: 35798000 Free PMC article. Clinical Trial.
Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variants.
Lyke KE, Atmar RL, Dominguez Islas C, Posavad CM, Deming ME, Branche AR, Johnston C, El Sahly HM, Edupuganti S, Mulligan MJ, Jackson LA, Rupp RE, Rostad CA, Coler RN, Bäcker M, Kottkamp AC, Babu TM, Dobrzynski D, Martin JM, Brady RC, Frenck RW Jr, Rajakumar K, Kotloff K, Rouphael N, Szydlo D, PaulChoudhury R, Archer JI, Crandon S, Ingersoll B, Eaton A, Brown ER, McElrath MJ, Neuzil KM, Stephens DS, Post DJ, Lin BC, Serebryannyy L, Beigel JH, Montefiori DC, Roberts PC; DMID 21-0012 Study Group. Lyke KE, et al. Among authors: rupp re. NPJ Vaccines. 2023 Jul 11;8(1):98. doi: 10.1038/s41541-023-00693-z. NPJ Vaccines. 2023. PMID: 37433788 Free PMC article.
Progress with COVID vaccine development and implementation.
Titball RW, Bernstein DI, Fanget NVJ, Hall RA, Longet S, MacAry PA, Rupp RE, van Gils M, von Messling V, Walker DH, Barrett ADT. Titball RW, et al. Among authors: rupp re. NPJ Vaccines. 2024 Apr 1;9(1):69. doi: 10.1038/s41541-024-00867-3. NPJ Vaccines. 2024. PMID: 38561358 Free PMC article. No abstract available.
The rapid progress in COVID vaccine development and implementation.
Barrett ADT, Titball RW, MacAry PA, Rupp RE, von Messling V, Walker DH, Fanget NVJ. Barrett ADT, et al. Among authors: rupp re. NPJ Vaccines. 2022 Feb 10;7(1):20. doi: 10.1038/s41541-022-00442-8. NPJ Vaccines. 2022. PMID: 35145102 Free PMC article. No abstract available.
Vaccines for sexually transmitted infections.
Rupp RE, Stanberry LR, Rosenthal SL. Rupp RE, et al. Pediatr Ann. 2005 Oct;34(10):818-20, 822-4. doi: 10.3928/0090-4481-20051001-14. Pediatr Ann. 2005. PMID: 16285635 Review.
A phase I randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and immunogenicity of a live-attenuated quadrivalent dengue vaccine in flavivirus-naïve and flavivirus-experienced healthy adults.
Russell KL, Rupp RE, Morales-Ramirez JO, Diaz-Perez C, Andrews CP, Lee AW, Finn TS, Cox KS, Falk Russell A, Schaller MM, Martin JC, Hyatt DM, Gozlan-Kelner S, Bili A, Coller BG. Russell KL, et al. Among authors: rupp re. Hum Vaccin Immunother. 2022 Nov 30;18(5):2046960. doi: 10.1080/21645515.2022.2046960. Epub 2022 Mar 15. Hum Vaccin Immunother. 2022. PMID: 35290152 Free PMC article. Clinical Trial.
Heterologous SARS-CoV-2 Booster Vaccinations - Preliminary Report.
Atmar RL, Lyke KE, Deming ME, Jackson LA, Branche AR, El Sahly HM, Rostad CA, Martin JM, Johnston C, Rupp RE, Mulligan MJ, Brady RC, Frenck RW Jr, Bäcker M, Kottkamp AC, Babu TM, Rajakumar K, Edupuganti S, Dobryzynski D, Posavad CM, Archer JI, Crandon S, Nayak SU, Szydlo D, Zemanek J, Dominguez Islas CP, Brown ER, Suthar MS, McElrath MJ, McDermott AB, O'Connell SE, Montefiori DC, Eaton A, Neuzil KM, Stephens DS, Roberts PC, Beigel JH; DMID 21-0012 Study Group. Atmar RL, et al. Among authors: rupp re. medRxiv [Preprint]. 2021 Oct 15:2021.10.10.21264827. doi: 10.1101/2021.10.10.21264827. medRxiv. 2021. PMID: 34671773 Free PMC article. Updated. Preprint.
Safety and Immunogenicity of a Delayed Heterologous Avian Influenza A(H7N9) Vaccine Boost Following Different Priming Regimens: A Randomized Clinical Trial.
El Sahly HM, Yildirim I, Frey SE, Winokur P, Jackson LA, Bernstein DI, Creech CB, Chen WH, Rupp RE, Whitaker JA, Phadke V, Hoft DF, Ince D, Brady RC, Edwards KM, Ortiz JR, Berman MA, Weiss J, Wegel A; DMID 17-0090 Study Group. El Sahly HM, et al. Among authors: rupp re. J Infect Dis. 2024 Feb 14;229(2):327-340. doi: 10.1093/infdis/jiad276. J Infect Dis. 2024. PMID: 37466221 Clinical Trial.
53 results